Page 38 - MELLBY_MAGASIN_2025_ENG_SID

ANOCCA

Bringing therapies to cancer
patients for the first time

With its TCR-T cell therapy approved for phase 1 clinical trials, the
biotechnology company Anocca is continuing its journey. Hopefully,
coming one step closer to more effective treatment for patients with

cancer and other serious diseases.

T-ells are the central decision-making and action-taking part
of the human body’s immune system. Anocca has developed
technologies that decipher T-cell immunity; to generate the
complex data required to inform how tailored therapies can be made
to fight cancer, autoimmune diseases and infections. Based on a
unique discovery platform, that uses programmable human cells to
recreate and manipulate T-cell immunity, Anocca creates libraries
of TCR-T cell therapies that cover a broad range of difficult to treat
cancer forms and patient populations.
THE NEXT STEPS FOR VIDAR-1
With focus on pancreatic cancer, one of the most difficult cancers
to treat, the company has transitioned into the next development
phase: early-stage clinical trials for Anocca’s lead programme
VIDAR-1.

“This year has been spot on!”, says Reagan Jarvis, CEO of Anocca.
“We have achieved this major milestone and are now bringing
therapies to patients for the first time.”

Having set up the trial formally at leading clinical centres across
Sweden, Denmark, Netherlands and Germany, the first patients have
already been enrolled and will be treated in the near future.

“The phase 1 clinical trials are focused on safety throughout 2026”,
says Reagan Jarvis. “Then we move into phase 2, which is formally
testing efficacy of the therapy, in 2027.”
KEY FACTORS FOR SUCCESS
It’s safe to say, that what Anocca is doing, engages the whole world.
The team consist of over 40 different nationalities – all gathered at
the headquarters in Södertälje, just south of Stockholm.

The team has been decisive
for our success

38